Receptors, Opioid, mu

• 

  Subject Areas on Research

  • A common single nucleotide polymorphism A118G of the μ opioid receptor alters its N-glycosylation and protein stability. 
  • A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism. 
  • An in vitro autoradiographic analysis of mu and delta opioid binding in the hippocampal formation of kindled rats. 
  • Ascaris suum, an intestinal parasite, produces morphine. 
  • Autoradiographic localization of benzomorphan binding sites in rat brain. 
  • Autoradiographic quantification of neurochemical markers of serotonin, dopamine and opioid systems in rat brain mesolimbic regions following chronic St John's wort treatment. 
  • Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. 
  • Central effect of mu-opioid agonists on antral motility in conscious rats. 
  • Central opioid receptors mediate morphine-induced itch and chronic itch via disinhibition. 
  • Child μ-opioid receptor gene variant influences parent-child relations. 
  • Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy. 
  • Depression of LTP in rat dentate gyrus by naloxone is reversed by GABAA blockade. 
  • Desensitization of G protein-coupled receptors and neuronal functions. 
  • Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. 
  • Early ontogeny of kappa-opioid receptor regulation of prolactin secretion in the rat. 
  • Effects of specific mu and kappa opiate tolerance and abstinence on hypothalamo-pituitary-adrenal axis secretion in the rat. 
  • Elevated mu-opioid receptor expression in the nucleus of the solitary tract accompanies attenuated withdrawal signs after chronic low dose naltrexone in opiate-dependent rats. 
  • Enhanced morphine analgesia in mice lacking beta-arrestin 2. 
  • Ethanol consumption by Fawn-Hooded rats following abstinence: effect of naltrexone and changes in mu-opioid receptor density. 
  • Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. 
  • Glafenine-induced intestinal injury in zebrafish is ameliorated by μ-opioid signaling via enhancement of Atf6-dependent cellular stress responses. 
  • Heterogeneity in presynaptic regulation of GABA release from hippocampal inhibitory neurons. 
  • Importance of voltage-dependent inactivation in N-type calcium channel regulation by G-proteins. 
  • Increased sensitivity to mu opiate antinociception in the neonatal rat despite weaker receptor-guanyl nucleotide binding protein coupling. 
  • Involvement of cAMP-dependent protein kinase in mu-opioid modulation of NMDA-mediated synaptic currents. 
  • Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. 
  • Morphine side effects in beta-arrestin 2 knockout mice. 
  • Mouse model of OPRM1 (A118G) polymorphism has altered hippocampal function. 
  • Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. 
  • Mu Opioid Splice Variant MOR-1K Contributes to the Development of Opioid-Induced Hyperalgesia. 
  • Mu opioid receptor-mediated modulation of synaptic currents in dentate granule cells of rat hippocampus. 
  • Mu- and kappa-opiate receptor control of prolactin secretion in rats: ontogeny and interaction with serotonin. 
  • Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. 
  • Mu-opioid receptors selectively regulate basal inhibitory transmission in the central amygdala: lack of ethanol interactions. 
  • Multiple endocytic pathways of G protein-coupled receptors delineated by GIT1 sensitivity. 
  • Nitric oxide production is enhanced in rat brain before oxygen-induced convulsions. 
  • Novel exonic mu-opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence. 
  • OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. 
  • Ontogeny of mu- and kappa-opiate receptor control of the hypothalamo-pituitary-adrenal axis in rats. 
  • Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterologous desensitization. 
  • Opioid-independent mechanisms supporting offset analgesia and temporal sharpening of nociceptive information. 
  • Opioid-mediated facilitation of long-term potentiation at the lateral perforant path-dentate granule cell synapse. 
  • Optogenetic model of opiate exposure. 
  • Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies. 
  • Peripheral axonal injury results in reduced mu opioid receptor pre- and post-synaptic action in the spinal cord. 
  • Pharmacogenomics for personalized pain medicine. 
  • Potentiated opioid analgesia in norepinephrine transporter knock-out mice. 
  • Quantitative autoradiographic analysis of mu and delta opioid binding sites in the rat hippocampal formation. 
  • Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. 
  • Robust age, but limited sex, differences in mu-opioid receptors in the rat brain: relevance for reward and drug-seeking behaviors in juveniles. 
  • Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. 
  • Role of mu-opioid and NMDA receptors in the development and maintenance of repeated swim stress-induced thermal hyperalgesia. 
  • Sortase ligation enables homogeneous GPCR phosphorylation to reveal diversity in β-arrestin coupling. 
  • Stabilization of μ-opioid receptor facilitates its cellular translocation and signaling. 
  • Suppression of alcohol intake by chronic naloxone treatment in P rats: tolerance development and elevation of opiate receptor binding. 
  • Synthesis and biological activity of a novel methylamine-bridged enkephalin analogue (MABE): a new route to cyclic peptides and peptidomimetics. 
  • The Impact of Alvimopan on Return of Bowel Function After Major Spine Surgery - A Prospective, Randomized, Double-Blind Study. 
  • The multifunctional peptide DN-9 produced peripherally acting antinociception in inflammatory and neuropathic pain via μ- and κ-opioid receptors. 
  • The novel micro-opioid receptor antagonist, [N-allyl-Dmt(1)]endomorphin-2, attenuates the enhancement of GABAergic neurotransmission by ethanol. 
  • The ontogeny of mu opiate tolerance and dependence in the rat: antinociceptive and biochemical studies. 
  • Transformation of mu-opioid receptor agonists into biologically potent mu-opioid receptor antagonists. 
  • beta-Endorphin-containing memory-cells and mu-opioid receptors undergo transport to peripheral inflamed tissue. 
  • mu-Opioid agonists stimulate growth hormone secretion in immature rats. 
  • β-arrestin-2 regulates NMDA receptor function in spinal lamina II neurons and duration of persistent pain. 
  • μ-Opioid Receptor Gene A118 G Variants and Persistent Pain Symptoms Among Men and Women Experiencing Motor Vehicle Collision. 
  • μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer.